AtaiBeckley to Begin BPL-003 Phase 3 Trials in Q2 2026 After FDA Clearance
AtaiBeckley will initiate Phase 3 studies of BPL-003 in Q2 2026 after FDA End-of-Phase 2 clearance, supported by Breakthrough Therapy designation and Phase 2b data showing rapid antidepressant effects in TRD. The company secured cash runway to early 2029, outlined plans for BPL-003 and expects VLS-01 Phase 2 topline in H2 2026.
1. BPL-003 Phase 3 Program Initiation
AtaiBeckley remains on track to launch two parallel Phase 3 trials—ReConnection-1 and ReConnection-2—in Q2 2026 after a successful FDA End-of-Phase 2 meeting. Each trial will feature a 12-week randomized, double-blind, placebo-controlled core study followed by a 52-week open-label extension to evaluate individualized retreatment criteria.
2. Cash Runway and Commercial Readiness
The company reaffirmed its cash runway into early 2029, ensuring funding for pivotal studies and commercial planning. AtaiBeckley detailed a scalable commercialization model for BPL-003 designed to integrate with existing interventional psychiatry workflows, emphasizing patient convenience and safety without in-session psychotherapy.
3. Pipeline Progress
Beyond BPL-003, AtaiBeckley highlighted positive Phase 2a results for EMP-01 in social anxiety disorder and anticipates topline data for VLS-01 in treatment-resistant depression in H2 2026. These developments underscore the company’s broader strategy to diversify its portfolio of rapid-acting mental health therapies.